Blood/brain barrier technetium complexes

Certain neutral technetium complexes can be used to image cerebral perfusion (Fig. 4). Those in Figure 4a and 4b have been approved for clinical use. Two other complexes (Fig. 4c and 4d) were tested in early clinical trials, but were not developed further. An effective cerebral perfusion agent must first cross the blood brain barrier and then be retained for the period necessary for image acquisition. Tc-bicisate is retained owing to a stereospecific hydrolysis in brain tissue of one of the ester groups to form the anionic complex TcO(ECD) , which does not cross the barrier. This mechanism of retention is termed metaboHc trapping. 

Blomstrand-Jorgensen chain theory, 1, 6 Blood coagulation calcium, 6,591 Blood/brain barrier brain imaging techniques technetium complexes, 6, 991 technetium complexes, 6,985 Blood plasma... 

PDPH has been used in the preparation of immunotoxin conjugates (Zara et al., 1991). It has also been used to create a unique conjugate of NGF with an antibody directed against the transferrin receptor OX-26, which could traverse the blood-brain barrier (Friden et al., 1993). Labeling of antibody molecules with PDPH at oxidized polysaccharide sites followed by reduction to free the sulfhydryl has been used to form a technetium-99m complex for radiopharmaceutical use (Ranadive et al., 1993) (Chapter 8, Section 2.5). 

---